|
| 36702070 | Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. | Breast | 2023 |
| 37597578 | Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. | Ann Oncol | 2023 |
| 37272756 | Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance. | Cancer Res | 2023 |
| 37265453 | Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 36332363 | Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. | EBioMedicine | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 33219484 | Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). | Breast Cancer Res Treat | 2021 |
| 33909203 | Neratinib⿿+⿿capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and⿿⿥⿿2 prior HER2-directed regimens. | Breast Cancer Res Treat | 2021 |
| 33591468 | The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+â¿¿and androgen receptor-positive metastatic or locally advanced breast cancer. | Breast Cancer Res Treat | 2021 |
| 33930605 | HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium. | Cell Mol Gastroenterol Hepatol | 2021 |
| 34551235 | Breast Cancer, <i>HER2</i> Mutations, and Overcoming Drug Resistance. | N Engl J Med | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 34173924 | Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 34339623 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. | Lancet Oncol | 2021 |
| 34028126 | Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. | Oncologist | 2021 |
| 33179922 | Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor. | J Phys Chem Lett | 2020 |
| 32067683 | Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. | Ann Oncol | 2020 |
| 30676778 | Imaging of HER2 with [<sup>89</sup>Zr]pertuzumab in Response to T-DM1 Therapy. | Cancer Biother Radiopharm | 2019 |
| 32923853 | Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. | JCO Precis Oncol | 2019 |
| 30857956 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. | Lancet Oncol | 2019 |
| 30787127 | Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. | J Natl Compr Canc Netw | 2019 |
| 29320312 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | J Clin Oncol | 2018 |
| 30181556 | The prognostic effects of somatic mutations in ER-positive breast cancer. | Nat Commun | 2018 |
| 29856693 | Reply to J.J. Tao et al. | J Clin Oncol | 2018 |
| 30429476 | Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer. | Nat Commun | 2018 |
| 29442264 | Evaluation of [<sup>89</sup>Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. | Breast Cancer Res Treat | 2018 |
| 27872189 | Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases. | J Biol Chem | 2017 |
| 35172500 | Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. | JCO Precis Oncol | 2017 |
| 28088451 | Efficient sortase-mediated N-terminal labeling of TEV protease cleaved recombinant proteins. | Anal Biochem | 2017 |
| 28138153 | CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. | Nat Genet | 2017 |
| 28743916 | Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types. | Sci Rep | 2017 |
| 28679771 | Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. | Clin Cancer Res | 2017 |
| 27078022 | Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial. | JAMA Oncol | 2016 |
| 27618449 | Unsupervised detection of cancer driver mutations with parsimony-guided learning. | Nat Genet | 2016 |
| 27146421 | [[89]Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. | Mol Imaging Biol | 2016 |
| 27284958 | Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. | Cancer | 2016 |
| 26987533 | Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. | Adv Exp Med Biol | 2016 |
| 26926684 | Genomic Characterization of Primary Invasive Lobular Breast Cancer. | J Clin Oncol | 2016 |
| 26124280 | Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. | Mol Cell Biol | 2015 |
| 26358790 | HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. | J Natl Compr Canc Netw | 2015 |
| 26508629 | HER2 missense mutations have distinct effects on oncogenic signaling and migration. | Proc Natl Acad Sci U S A | 2015 |
| 26243863 | HER2 activating mutations are targets for colorectal cancer treatment. | Cancer Discov | 2015 |
| 26209800 | Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. | Bioinformatics | 2015 |
| 24723360 | Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. | Electrophoresis | 2014 |
| 23105007 | Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. | Mol Cell Proteomics | 2013 |
| 24298067 | Incorporating genomics into breast cancer clinical trials and care. | Clin Cancer Res | 2013 |
| 24122041 | DGIdb: mining the druggable genome. | Nat Methods | 2013 |
| 24055055 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. | Cell Rep | 2013 |